Novartis AG R&D Day Transcript

Nov 28, 2023 / 01:30PM GMT
Samir Shah - Novartis AG - Global Head of IR

So on behalf of Novartis, just want to welcome you all to our R&D Day here in London, and also to say a big thank you for making the time for all of you to come here and participate, and for everybody else who's on the web. So thank you.

Before we start, the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that, respectively, were filed with and furnished to the U.S. Securities and Exchange Commission.

I think for the people who are here, they've got a printout of all the deck slides, and people on the web also can find it on the Novartis website. The agenda is a fairly packed agenda. We're going to begin with Novartis strategy and growth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot